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SUMMARY 
Complement C5 deficiency (C5D) is a rare primary immunodeficiency associated with recurrent 
infections, particularly meningitis, by Neisseria species. To date, studies to elucidate the molecular 
basis of hereditary C5D have included fewer than 40 families, and most C5 mutations (13 of 17) 
have been found in single families. However, the recently described C5 p.A252T mutation is 
reported to be associated with approximately 7% of meningococcal disease cases in South Africa. 
This finding raises the question of whether the mutation may be prevalent in other parts of Africa or 
other continental regions. The aim of this study was to investigate the prevalence of C5 p.A252T in 
Africa and other regions and discuss the implications for prophylaxis against meningococcal 
disease. In total, 2710 samples from healthy donors within various populations worldwide were 
analysed by quantitative polymerase chain reaction (qPCR) assay to detect the C5 p.A252T 
mutation. Eleven samples were found to be heterozygous for p.A252T, and nine of these samples 
were from sub‐Saharan African populations (allele frequency 0·94%). Interestingly, two other 
heterozygous samples were from individuals in populations outside Africa (Israel and Pakistan). 
These findings, together with data from genomic variation databases, indicate a 0·5–2% prevalence 
of the C5 p.A252T mutation in heterozygosity in sub‐Saharan Africa. Therefore, this mutation may 
have a relevant role in meningococcal disease susceptibility in this geographical area. 
 
 
INTRODUCTION 
The complement system has a major role in the innate immune system's defence against pathogens. 
Complement activation upon recognition of certain molecular patterns by any of the three pathways 
leads to activation of a common terminal complement pathway1, 2. C5 is the initial component of 
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this pathway, and activation through the C5 convertases releases the potent anaphylatoxin peptide 
C5a and generates C5b. After C5 cleavage, the terminal components C6, C7, C8 and C9 bind to 
produce the membrane attack complex (MAC), which forms a hydrophilic channel through the 
membrane of target cells, causing cell death3. The pores that the MAC generates on a pathogen's 
surface are key to host defence against Gram‐negative bacteria, particularly species from the 
Neisseria genus4. 
During recent decades, deficiencies of the terminal complement components that form the MAC 
(C5‐C9) have been described extensively5. The risk of meningococcal disease in patients with these 
deficiencies is 7000–10 000‐fold higher than that of healthy individuals, and they also have a higher 
risk of recurrent invasive meningococcal infection6, 7. In general, terminal complement deficiencies 
are rare, but the incidence varies considerably between different populations. A well‐recognized 
example is C9 deficiency, caused mainly by the non‐sense mutation, R95X. In Japan, it is one of the 
most common genetic disorders, with a population prevalence of one in 1000, whereas only a few 
patients with C9 deficiency have been identified in European countries8. C7 deficiency caused by 
the G357R mutation is reported as having a high prevalence (1·1%) in the Israeli Moroccan Jewish 
population9, and C6 deficiency has a high prevalence in Western Cape South Africans and in 
African Americans10-13. 
Focusing upon C5 deficiency, approximately 50 cases have been published from around the 
world14-22 and most of the causal mutations have been described in only one family. A striking 
exception is the p.A252T mutation, reported recently to be responsible for C5 deficiency and found 
in approximately 7% of meningococcal disease cases in black Africans from the Western Cape 
(South Africa)21. This mutation has an allele frequency of 3% in the black African population and 
0·66% in the Cape Coloured population of the Western Cape area21. 
Meningococcal meningitis cases occur throughout the world. However, large, recurrent epidemics 
affect an extensive region of sub‐Saharan Africa known as the ‘meningitis belt’, which covers 26 
countries from Senegal in the West to Ethiopia in the East23. Considering the previously observed 
allelic distribution of p.A252T in South Africa, the question arises as to whether the mutation may 
be prevalent in other parts of Africa or other continental regions. The aim of this study was to 
evaluate the presence of the C5 p.A252T mutation in Africa and other continental regions and 
discuss the implications for prophylaxis against meningococcal disease. 
 
 
MATERIALS AND METHODS 
Samples 
In total, 2710 gDNA samples were tested. Almost half these samples (n = 1064) were a part of the  
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Human Genome Diversity Panel (HGDP), a widely used resource for studies of human genetic 
variation. Genomic DNA samples from these fully consenting individuals were collected by the 
Human Genome Diversity Project in collaboration with the Centre Etude Polymorphism Humain 
(CEPH) in Paris. Fifty‐one different populations from Africa, Europe, the Middle East, South and 
Central Asia, East Asia, Oceania and the Americas are represented in the HGDP24, 25. 
To increase the number of samples from Africa, a collection of 352 samples from Gabon and 768 
samples from North African countries (Morocco, Algeria, Tunisia and Libya) were also included. 
The presence of the mutated allele was also evaluated in 526 local samples (Barcelona, Spain) 
obtained from blood donors. 
Although all the samples included in the study were from healthy individuals, a history of previous 
meningococcal disease was not recorded specifically. All samples were collected with the informed 
consent of the volunteers participating in the study. 
 
Screening for the C5 p.A252T mutation 
Quantitative polymerase chain reaction (qPCR) assay design 
The properly tagged consensus sequence containing the C5 c.754G > A (p.A252T) variant and all 
other single nucleotide polymorphisms (SNPs) in the vicinity was submitted to the design tool at the 
Applied Biosystems website for custom TaqMan assay design. The TaqMan genotyping assay mix 
contained a forward and reverse primer for the submitted sequence, one probe that matched 
perfectly the wild‐type sequence variant (c.754G) labelled with VIC, and a second probe that 
matched the mutant (c.754A) variant, labelled with FAM. 
Allele discrimination assay 
To obtain a final PCR volume of 10 μl, a working master mix was prepared containing 0·25 μl of 
TaqMan genotyping assay mix (×40), 5 μl TaqMan UNG Master Mix ×2 (Applied Biosystems, 
Carlsbad, CA, USA) and 2·75 μl of water for each reaction. Samples were placed directly into each 
well of a 96‐well plate. Two controls for each condition (wild‐type, heterozygous for the mutation 
and homozygous for the mutation) were used in each assay. Plates were loaded onto an Applied 
Biosystems 7500 fast real‐time PCR system, and the 7500 (version 2.0.5) software was used to run 
the assay, following the default standard allelic discrimination genotyping assay protocol. Briefly, 
this consisted of an end‐point PCR in which fluorescence was read prior to PCR and after 
completion of the last PCR cycle. The software calculated the normalized dye fluorescence (ΔRn) 
as a function of cycle number for allele 1 (wild‐type) and allele 2 (mutant). The results were 
displayed on a plot, where each axis represented the fluorescence level of each fluorochrome, thus 
grouping the samples on the three different genotypes (Figure. 1a). 
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Sanger sequencing 
Samples identified as heterozygous for the c.754G > A/p.A252T mutation by the qPCR genotyping 
assay were then confirmed by Sanger sequencing of C5 exon 7 (Figure. 1b). 
 
 
RESULTS 
The C5 p.A252T mutation is prevalent in, but not restricted to, sub‐Saharan Africa 
Screening for the C5 c.754G > A/p.A252T mutation was carried out in 2710 samples from different 
populations worldwide. Initially, to provide a general view of p.A252T distribution, we grouped the 
samples into seven continental regions and calculated the frequencies of the mutated allele in each 
one (Table 1). Results for individual populations are shown in the Supporting information, Table 
S1. In total, 11 samples heterozygous for the p.A252T mutation were found, resulting in an overall 
mutated allele frequency of 0·2% in our samples. However, the distribution of the mutation was not 
random: sub‐Saharan Africa populations showed the highest number of mutated alleles, with nine 
heterozygous samples among the 958 tested (allele frequency 0·94%). These included seven 
heterozygous samples among 352 individuals tested in Gabon (allele frequency 1%), one of 25 in 
Nigeria (allele frequency 2%) and one of eight in South Africa (allele frequency 6·25%) (Table 2). 
In this last case, and to lesser extent in Nigeria, the allele frequency was probably over‐estimated 
because of the small number of samples tested. 
Interestingly, we found two heterozygous samples from other continental regions: one from Israel 
(Middle East and North Africa region) and one from Pakistan (Central and South Asia region). The 
mutation was absent in the remaining continental regions studied. 
Overall analysis of the C5 p.A252T mutation worldwide distribution 
The C5 c.754G > A/p.A252T allelic variation is reported in the SNP database (dbSNP) (code 
rs112959008), and has an overall minor allele frequency (MAF) of 0·0012, as reported in the 1000 
Genomes Project26. However, as our results indicate, there are huge differences in this frequency 
depending on the continental region. Within the 1000 Genomes Project (1000G), the mutated allele 
was reported in individuals from Barbados (of African origin), Nigeria and Kenya (Table 3), with 
an overall estimated heterozygosity of 1–2% in these Central African countries. This data is 
concordant with our reported heterozygosity in Gabon (1%). The p.A252T mutation was not found 
in any of the other populations examined in 1000G, which unfortunately does not include samples 
from South Africa or countries in the Middle East/North Africa. 
Further evidence of the higher prevalence of the p.A252T mutation in Africa relies upon a report 
from the National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (ESP). In 
the ESP, the mutated allele was identified in in 15 of 2090 samples from African American 
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individuals (allele frequency, 0·36%) (Table 3). In contrast, it was not found in any of the 4044 
samples tested from Americans of European ancestry. 
Recently, Owen et al. investigated the incidence of the mutated allele in 1500 samples from South 
African neonates. The allele was present in both black Africans and Cape Coloured individuals, 
with allelic frequencies of 3 and 0.66%, respectively21. The populations in which the C5 p.A252T 
mutation has been detected, together with their heterozygosity frequencies, are summarized in 
Table 3. 
 
 
DISCUSSION 
The MAC has a major role in defending the host from Neisseria infection, but it cannot form if any 
of the five final complement components are absent. Consequently, C5 deficiency (C5D, OMIM 
#609536) is associated with recurrent episodes of infection by Neisseria species, particularly 
meningitis and extragenital gonorrhoea. To date, studies to elucidate the molecular basis of 
hereditary C5D have included more than 30 families, with descriptions of 17 different mutations22 
distributed randomly along the C5 gene, and including missense, non‐sense, insertion–deletion and 
splicing mutations. Most C5 mutations (13 of the 17) have been described in only one family22.  
The most relevant exception to this general observation is the p.A252T mutation, reported by 
Owen et al.21. 
The results of our study, together with data recorded in public databases, demonstrate the high 
prevalence of p.A252T in sub‐Saharan Africa, and show for the first time the presence of this 
mutation in regions outside Africa (Middle East and South Asia). 
Although it is difficult to establish the true frequency of the mutation, our results may be helpful for 
outlining an estimate. As shown in Table 3, various unrelated data have proved the presence of the 
A252T variant in heterozygosity in healthy individuals from several parts of Africa, and our results 
broaden the distribution of this mutation to other regions, specifically Israel and Pakistan. 
However, when interpreting the frequency of p.A252T, several factors must be considered, 
particularly the size and origin of the population studied. The specific populations included in the 
1000G and HGDP used in this study are well defined, but relatively small in size (around 100 
individuals or less). To increase the representation from Africa, we collected 352 samples from 
Gabon (Central Africa) and 768 from North African countries (Morocco, Algeria, Tunisia and 
Libya). Other relevant data were provided by the 2090 African American individuals within the 
NHLBI Exome Sequencing Project (although their specific origin is not reported) and the 1500 
individuals from South Africa described by Owen et al.21. Based on the data from the present study 
and the above‐mentioned available information, we estimated the heterozygosity frequency of the 
C5 p.A252T mutation in sub‐Saharan Africa to be 0·5–2%. The true accuracy of this frequency and 
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whether it substantially varies between the different populations in the region are questions that 
remain to be elucidated in studies with larger sample sizes. What seems clear, however, is that the 
high prevalence of this mutation in Africa is restricted to the sub‐Saharan region, as no carriers 
were found among the 768 samples from North African countries. Nevertheless, we cannot exclude 
the possibility that the mutation is present at a low frequency in North Africa. 
Based on these data, it seems likely that the C5 p.A252T mutation could have a relevant role in 
meningococcal disease susceptibility in sub‐Saharan Africa. In all individuals homozygous for 
p.A252T, C5 protein levels are < 4% of the mean control level measured by enzyme‐linked 
immunosorbent assay (ELISA) and are undetectable by Western blot21, providing proof of the 
functional importance of this mutation. The amino acid A252 is highly conserved among the 
species (Supporting information, Figure S1), and estimation of the putative pathogenicity of A252T 
using two widely used prediction software packages (SIFT and PolyPhen‐2) indicated that 
pathogenicity was probable. Therefore, p.A252T homozygosity would lead to de‐facto C5 
deficiency (with extremely low serum C5 protein levels) and a high susceptibility to meningococcal 
disease. 
Why this mutation has survived evolutionary pressure is a question still to be answered. It is 
reported that individuals with deficiencies of late complement components have a lower incidence 
of septic shock after Neisseria meningitides infection, which results in lower mortality from this 
disease7. Following this rationale, it is possible that carriers of the mutation in the meningitis belt 
countries of sub‐Saharan Africa would have some protection from septic shock during infection by 
this pathogen, thus increasing their chances of survival. Nonetheless, meningococcal disease is 
often associated with serious sequelae, such as a loss of digits or limbs, or persistent neurological 
damage. Hence, emphasis should be placed upon prevention of the disease through vaccination. 
Based on the lower range of the estimated frequency of C5 p.A252T heterozygosity in this study 
(0·5%) and considering a population of 1 billion individuals living in sub‐Saharan Africa, a few 
million heterozygous and thousands of homozygous individuals with C5 deficiency would be living 
in this area. These estimated values should be confirmed in further studies including a significantly 
larger sample size from countries within the meningitis belt. It would also be interesting to evaluate 
the prevalence of p.A252T in meningococcal disease patients in sub‐Saharan African countries, 
which could be carried out with the simple, low‐cost method used in the present study. Moreover, if 
the prevalence of the mutation is as high as suspected, a routine test could be used to detect it and 
facilitate a prompt diagnosis of complement deficiency27. 
Many countries outside Africa have been a common destination for African immigrants over the 
years; consequently, the mutation can be spread to other countries. An example of this occurred in 
the present study. We collected 527 local samples, and after rigorous selection to ensure their 
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European origin, one of them was excluded from the study because it came from an individual from 
The Gambia. The sample was tested and was found to carry the mutated allele in heterozygosis. 
In summary, the C5 p.A252T mutation is indeed prevalent in sub‐Saharan Africa. Testing for this 
mutation in meningococcal disease patients would be of value to identify C5‐deficient individuals. 
A further step would be newborn screening, which could enable more effective prevention of the 
primary disease through vaccination. 
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Table 1. 
Allelic frequencies of the C5 c.754G > A/p.A252T mutation 
Continental region Alleles 
tested 
Mutated alleles Mutated allele 
frequency (%) 
Sub‐Saharan Africa 958 9 0·94 
America 216 0 0 
East Asia 502 0 0 
Central and South Asia 400 1* 0·25 
Middle East and North 
Africa 
1892 1a 0·05 
Oceania 78 0 0 
Europe 1374 0 0 
All mutated alleles detected correspond to heterozygous individuals. *Individual from 
Pakistan; †individual from Israel (Negev). 
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Table 2 
Allelic frequencies of c.754G > A/p.A252T in sub‐Saharan African countries 
Country Alleles 
tested 
Mutated alleles Mutated allele frequency (%) 
South Africa 16 1 6·25 
Kenya 24 0 0 
Namibia 14 0 0 
Central African Republic 72 0 0 
Nigeria 50 1 2 
Democratic Republic of 
Congo 
30 0 0 
Gabon 704 7 1 
Senegal 48 0 0 
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Table 3 
Review of the reported populations with presence of C5 p.A252T mutation 
Population Heterozygosity 
frequency (%) 
Count (total) Source 
Africa 
   
Barbados (African 
Caribbean) 
2·1 2 (96) 1000G 
Nigeria (Esan) 2 2 (98) 1000G 
Kenya (Luhya in 
Webuye) 
1 1 (99) 1000G 
Nigeria (Yoruba in 
Ibadan) 
0·93 1 (108) 1000G 
African American 0·72 15 (2090) NHLBI Exome 
Sequencing Project 
South Africa (black 
Africans) 
6 45 (750) Owen et al. 
South Africa (Cape 
Coloured) 
1·33 10 (750) Owen et al. 
South Africa (Bantu 
S.U. Zulu) 
12·5 1 (8) This study 
Nigeria (Yoruba) 4 1 (25) This study 
Gabon 1·99 7 (352) This study 
South Asia 
   
Pakistan 0·5 1 (200) This study 
Middle East 
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Population Heterozygosity 
frequency (%) 
Count (total) Source 
Israel (Negev) 2 1 (49) This study 
1000G = 1000 Genomes Project; NHLBI = National Heart, Lung and Blood Institute 
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Figure 1 
(a)   Allelic Discrimination Plot 
 
 
 
C5 p.A252T mutation screening. (a) Cluster plot of 96 DNA samples that 
underwent C5 p.A252T mutation genotyping by TaqMan assay using the 
Applied Biosystems 7500 real‐time polymerase chain reaction (RT–PCR) 
system. Red indicates wild‐type homozygous samples (A252). Green 
indicates heterozygous samples. Blue indicates mutated homozygous 
samples (T252). Black indicates the negative controls. Two controls for 
each genotype were included in all plates. (b) Sanger sequencing of one 
heterozygous carrier of the C5 p.A252T mutation. All heterozygous 
samples detected by quantitative PCR were sequenced to confirm the 
results. [Colour figure can be viewed at wileyonlinelibrary.com] 
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